The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

Program Outline

SGLT in the Intestine

SGLT in the Kidney

SGLT in the Kidney (cont)

Inhibition of SGLT

Inhibition of SGLT: Kidney

Inhibition of SGLT: Kidney and Intestine

Approval of SGLT Inhibitors

SGLT Inhibition in T2DM

Dapagliflozin Monotherapy 2-Year Study

Effect of SGLT-2 Inhibitors on HbA1c, SBP, and Bodyweight

CV Outcomes Trials With SGLT-2 Inhibitors in T2DM

Empagliflozin and Renal Parameters in EMPA-REG

CV Outcomes Trials: Renal Outcome Data

SGLT-2 Inhibition: Cardio-Renal Effects

SGLT Inhibition -- Expanding Opportunities

Unmet Need in T1DM

DEPICT-1 Trial: Dapagliflozin Adjunct to Insulin in T1DM

EASE Trials: Empagliflozin Adjunct to Insulin in T1DM

InTandem Trials: Sotagliflozin Adjunct to Insulin in T1DM

InTandem 3 Trial

Sotagliflozin: Reduction in Glucose Variability

Adverse Events With SGLT Inhibitors

Adverse Events: SGLT2 Inhibitors vs GLP-1 RAs

SGLT Inhibitors and DKA

SGLT Inhibitors and DKA (cont)

SGLT Inhibitors and DKA (cont)

International Consensus on DKA in T1DM With SGLT Inhibitors

International Consensus on DKA in T1DM With SGLT Inhibitors (cont)

Amputations: Clinical Trial and Real-World Data

Summary

Abbreviations

Abbreviations (cont)